@article{8178965e3f484fdabbd478c808328140,
title = "Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1",
keywords = "Biodistribution, Dosimetry, GluN2B-subunit, Neuropsychiatric disorders, NMDA receptor, PET, RADIATION-DOSIMETRY, LIGAND",
author = "Lucas Rischka and Matej Murga{\v s} and Verena Pichler and Chrysoula Vraka and Ivo Rausch and Dietmar Winkler and Lukas Nics and Sazan Rasul and Silberbauer, \{Leo Robert\} and Reed, \{Murray Bruce\} and Godbersen, \{Godber Mathis\} and Jakob Unterholzner and Patricia Handschuh and Gregor Gryglewski and Thomas Mindt and Markus Mitterhauser and Andreas Hahn and Ametamey, \{Simon Mensah\} and Wolfgang Wadsak and Rupert Lanzenberger and Marcus Hacker",
note = "Funding Information: This project was supported in part by the Swiss National Science Foundation grant numbers 310030E-160403/1 and 310030E-182872/1 to Prof. Simon M. Ametamey. Matej Murga{\v s} is funded by the Austrian Science Fund FWF DOC 33-B27. Murray B. Reed and Leo R. Silberbauer are recipients of a DOC fellowship of the Austrian Academy of Sciences. Funding Information: The authors are particularly grateful to Pia Baldinger-Melich and Paul Michenthaler for clinical support. We thank Vera Ritter, Christoph Wotawa, Daniel Pacher, Sebastian Klug, Harald Ibeschitz, Natalie Schindler, Karsten Bamminger, Tim Wollenweber and Marius Ozenil for technical support. Furthermore, the authors also thank Yves Auberson and Nicholas Seneca from Novartis for their technical support. Funding Information: S. M. Ametamey is co-inventor of the filed patent number US2017/0224852A1. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. D. Winkler received lecture fees/authorship honoraria within the last three years from Angelini, Lundbeck, MedMedia Verlag, and Medical Dialogue. Without relevance to this work, W. Wadsak received within the last 3 years research grants from ITM Medical Isotopes GmbH (Munich, Germany) and Scintomics (F{\"u}rstenfeldbruck, Germany). Without relevance to this work, M. Mitterhauser is scientific advisor for ROTOP Pharma GmbH. All other authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
doi = "10.1186/s13550-022-00925-8",
language = "English",
volume = "12",
journal = "EJNMMI Research",
issn = "2191-219X",
publisher = "SPRINGEROPEN",
number = "1",
}